NFE2L2 and colitis: Tussilagone, a molecule able to inhibit NF-κB activation and to induce Nrf2, reduced the main markers of murine colitis induced by DSS (i.e., TNF-α and IL-6) suggesting its potential role in the treatment of colitis [82].